Screener
Relmada Therapeutics, Inc. RLMD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.09M-32.3% | $8.07M-26.6% | $4.04M-63.8% | $2.82M-73.7% | $11.95M-10.2% | ||
| $11.37M+81.5% | $12.26M+51.8% | $6.29M-47.0% | $7.4M-8.6% | $6.27M-35.3% | ||
| $19.46M+6.8% | $20.33M+6.6% | $10.33M-55.1% | $10.22M-45.7% | $18.22M-20.7% | ||
| -$19.46M-6.8% | -$20.33M-6.6% | -$10.33M+55.1% | -$10.22M+45.7% | -$18.22M+20.7% | ||
| $409.8K-37.8% | $465.35K+11.2% | $235.85K-81.6% | $354.86K-66.2% | $658.97K-43.2% | ||
| -$19.05M-8.5% | -$19.87M-6.5% | -$10.09M+53.6% | -$9.87M+44.5% | -$17.56M+19.6% | ||
| -$0.22+62.1% | -$0.29+53.2% | -$0.30+58.3% | -$0.30+49.2% | -$0.58+19.4% | ||
| -$19.46M-6.8% | -$20.33M-6.6% | -$10.33M+55.1% | -$10.22M+45.7% | -$18.22M+20.7% |
FAQ
- Is Relmada Therapeutics, Inc. profitable?
- Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s earnings per share?
- Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.
- Where does Relmada Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.